# COVID-19 Prophylaxis South Africa (COVER HCW)

> **NCT04561063** · PHASE2 · COMPLETED · sponsor: **University of Witwatersrand, South Africa** · enrollment: 1950 (actual)

## Conditions studied

- Covid19
- SARS-CoV Infection

## Interventions

- **DRUG:** Nitazoxanide
- **DRUG:** Sofosbuvir/Daclatasvir

## Key facts

- **NCT ID:** NCT04561063
- **Lead sponsor:** University of Witwatersrand, South Africa
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-08
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 1950 (ACTUAL)
- **Last updated:** 2022-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04561063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04561063, "COVID-19 Prophylaxis South Africa (COVER HCW)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04561063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*